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With great interest we read the article of Barst et al. [1].
We agree with their statement that the deﬁnition of a
positive acute vasodilator response in patients with pul-
monary arterial hypertension (PAH) remains controversial.
We believe it is very important to minimize this contro-
versy and use uniform criteria when studying the acute
pulmonary vasodilator response in patients with PAH.
In their article, Barst and coworkers deﬁned acute
response criteria based on a 20% or more decrease in
mean pulmonary arterial pressure (mPAP) with no
decrease in cardiac index, or on a 25% or more decrease
in the pulmonary vascular resistance index (PVRI) with
no decrease in cardiac index (the latter only in case of an
unrestricted shunt at the ventricular or ductal level). We
do not recognise these criteria from previously published
reports. A review of the literature provides the following
deﬁnitions of a positive response to acute pulmonary
vasodilator tests:
1. An mPAP decrease of 20% or more, no decrease in
cardiac index and no change or a decrease in the
pulmonary-to-systemic vascular resistance ratio [2, 3]
2. A decrease of more than 20% in both mPAP and PVRI
[4, 6]
3. A fall in total pulmonary resistance of more than 30%
[7]
4. A decrease in mPAP of 10 mmHg or more, reaching
an mPAP of 40 mmHg or less and a normal cardiac
output [5].
To our knowledge, the criteria used in the current article
have not been published previously. The use of different
response criteria in different studies results in different
prevalences of acute vasodilator response and different
predictive values for identifying long-term responders to
calcium-channel blocker treatment and patients with
improved survival [5].
Furthermore, as a result, data from these studies cannot
be compared directly. For example, the prevalence of acute
responders among children with PAH (42%) is reported to
be higher than among adults (12–26%) [2, 4, 5]. However,
because the criteria used differed between children and
adults, this comparison does not hold.
We commend Barst and coworkers for their success in
comparing the use of different vasodilating agents (inhaled
nitric oxide, oxygen, or the combination of the two) for
vasodilator testing in children. However, the introduction
again of new response criteria prohibits interpretation of
these data in the perspective of previously published data.
It is not our intention to discourage the quest for new
response criteria aimed at reaching better prediction of
treatment effect or survival or at expanding its use to
broader patient populations other than those with idiopathic
PAH (iPAH) or familial PAH (FPAH). However, in view
of the ongoing discussion on the optimal deﬁnition of acute
response criteria, we strongly advocate presenting the use
of new criteria in a manner comparative with the use of
previously published criteria.
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